New biomimetic heart valve faces off against standard TAVR in major trial
Disease control
Recruiting now
This study compares a new heart valve, the DurAVR®, to standard TAVR valves in people with severe aortic stenosis (a narrowed heart valve). About 1650 participants will be randomly assigned to get either the new valve or a standard one and will be followed for up to 10 years. The…
Phase: NA • Sponsor: Anteris Technologies Ltd. • Aim: Disease control
Last updated May 26, 2026 12:04 UTC